News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TG Therapeutics, Inc. (MHA) Announces Investigational New Drug (IND) for TGTX-1101, Receives Clearance by the FDA to Commence Clinical Trials in the U.S.


5/15/2012 9:37:06 AM

NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (the "Company") - announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug Application ("IND") for TGTX-1101, also known as ublituximab, a novel third generation chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen found on B lymphocytes. The Company is now permitted to commence its Phase 1/2 clinical trial in patients with B-cell Lymphomas, which it plans to do this summer.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES